Healthcare Industry News:   Novation 

Devices Oncology Group Purchasing

 News Release - June 14, 2006

ONCURA(TM) Signs Agreement with Novation to Provide Prostate Brachytherapy Products for a New Three-Year Term

PLYMOUTH MEETING, Pa., June 14 (HSMN NewsFeed) -- ONCURA, a global leader in the minimally invasive management of prostate cancer, and Novation, LLC, the health care contracting services company of VHA Inc. and the University Health System Consortium (UHC), announced today that ONCURA has been awarded a three- year contract to provide VHA Inc. and UHC members with a complete portfolio of prostate brachytherapy products. The three-year agreement was effective from June 1, 2006 and offers ONCURA's Iodine-125 and Palladium-103 products.

"We are delighted that Novation has chosen to continue working with ONCURA," said Andrew Bright, ONCURA's Vice President, Brachytherapy Americas. He added, "With Novation's commitment to combine economies of scale with clinical knowledge and product excellence and our dedicated brachytherapy team, together we can increase the number of prostate cancer patients who benefit from brachytherapy."

Since the early 1990s ONCURA and its predecessor Amersham have been committed to innovation in prostate brachytherapy. Products include the groundbreaking RAPID Strand(TM), which has benefited from extensive clinical experience and is the subject of peer-reviewed publications that have demonstrated its clinical value. In addition, ONCURA offers VHA and UHC members OncoSeed(TM), the original I-125 seed, benefiting from more clinical experience and long-term survival data than any other prostate brachytherapy seed. RAPID Strand contains the same seed and benefits from the same long-term data. ONCURA also provides EchoSeed(TM), with its enhanced clinical recognition features, and ProsperaŽ Palladium-103 seeds.

About ONCURA

ONCURA was created through the merger of Amersham plc's (now GE Healthcare) brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. Please visit http://www.oncura.com for more information.

About Novation

Based in Irving, Texas, Novation is the leading health care contracting services company, delivering unmatched savings and value to nearly 2,500 members of VHA Inc. and the University Health System Consortium (UHC), two national health care alliances. Through its public competitive bid process, Novation develops and manages contracts with more than 700 suppliers, both large and small. By combining scale and agility with clinical knowledge and product expertise, Novation offers the most extensive range of innovative contracting services, including: contract development, contract and supplier management, custom contracting, enhanced savings programs, online contract management and analytical tools, order management and online supplier connectivity. VHA and UHC members used Novation's contracts to purchase more than $25 billion in supplies in 2005.


Source: ONCURA

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.